Thermo Fisher Scientific TMO has introduced biobased films that can help reduce the climate impact on the manufacturing of therapies, thereby increasing the sustainability of biologics therapies development. The first-of-its-kind solutions build on the company’s existing Aegis and CX film offerings that are widely used and validated by customers. The company is helping biopharma manufacturers reduce their environmental impact without having to validate new bioprocessing containers (BPCs), thus helping them speed up treatment deliveries. The recent development is also likely to enhance its BioProduction business under the Life Science Solutions segment. More on the News Instead of fossil fuel materials, Thermo Fisher has leveraged plant-based materials to deliver lower-carbon, biobased films for its single-use technology BPCs. This enables customers to maintain consistency in their BPCs while also achieving a reduction in greenhouse gas (GHG) emissions. By adopting these biobased, sustainable films, they can eliminate carbon emissions coming from the plastic resin. The biobased films have earned an International Sustainability and Carbon Certification (“ISCC”) PLUS certification, a top global certification for circular and biobased products. Biopharma manufacturers can now pre-purchase the biobased films to incorporate into their upstream or downstream system in early 2025. Thermo Fisher will also help customers as they monitor their carbon reduction quantities and support their sustainability objectives. Zacks Investment Research Image Source: Zacks Investment Research In addition to offering BPCs with biobased film, Thermo Fisher connects customers with recyclers to facilitate the recycling of BPCs post-use. This program helps biopharma manufacturers to divert waste from landfills or carbon-intensive incineration, advancing their sustainability goals through a convenient recycling service that turns BPCs into high-quality plastic lumber. Since the initiation of the program, approximately 400,000 pounds of plastic waste have been diverted from landfills or incineration. Significance of Sustainability Efforts The company is exploring new ways to design, produce, package and ship products to reduce the environmental impacts of the industry while still maintaining the expected quality and performance. Thermo Fisher also showcased further commitment to sustainable practices and responsible manufacturing by earning an ISCC PLUS certification for producing biobased resins in its Nunc Cell Factory product line, which is used in the development of vaccines and biologics. These latest innovations and initiatives are intended to help Thermo Fisher’s customers drive sustainability as they tackle some of the most challenging medical issues in the world. The company focuses on five key areas of environmental impact for greener innovation, which are minimizing the use of hazardous materials, reducing waste and using fewer resources, increasing energy efficiency, responsibly packaging and shipping and extending the useful life of products and materials. The scientists at Thermo Fisher apply Design for Sustainability principles to design products, creating more sustainable options as part of its Greener by Design portfolio to help advance sustainability and improve lab safety. Industry Prospects Per a Precedence Research report, the global bio-based packaging market was valued at $7.92 billion in 2022 and is expected to witness a CAGR of 12.6% up to 2032. Plant-based materials like cellulose nanocrystals and biopolymers can replace non-recyclable layers in plastic packaging to improve recyclability. Consumers and the government support the use of bio-based packaging and coatings to reduce plastic waste. Recent Developments in the Life Science Solutions Division Last month, Thermo Fisher expanded the Thermo Scientific KingFisher instrument portfolio with PlasmidPro Maxi Processor (PlasmidPro). The system enables innovation at scale by providing complete automation across mini and maxi-scale purification and delivering high-purity plasmids without manual column preparation and intervention. The company’s new “press and go” solution accelerates the purification process, catering to the rapidly growing demand for plasmid DNA purification for emerging therapies. Price Performance In the past year, TMO shares have rallied 2.8% compared with the industry’s rise of 3.1%. Zacks Rank and Key Picks Thermo Fisher currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Hims & Hers Health HIMS, ResMed RMD and Medpace MEDP. While Hims & Hers Health sports a Zacks Rank #1 (Strong Buy), ResMed and Medpace carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks Rank #1 stocks here. Hims & Hers Heath shares have surged 132.8% in the past year. Estimates for the company’s earnings have increased from 19 cents to 20 cents in 2024 and from 35 cents to 38 cents in 2025 in the past seven days. HIMS’ earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. In the last reported quarter, it posted an earnings surprise of a staggering 150%. Estimates for ResMed’s fiscal 2024 earnings per share have remained constant at $7.70 in the past 30 days. Shares of the company have plunged 11.8% in the past year compared with the industry’s decline of 2.2%. RMD’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 10.9%. Estimates for Medpace’s 2024 earnings per share have remained constant at $11.29 in the past 30 days. Shares of the company have surged 69.2% in the past year compared with the industry’s 5.3% growth. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO):Free Stock Analysis Report ResMed Inc. (RMD):Free Stock Analysis Report Medpace Holdings, Inc. (MEDP):Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Thermo Fisher (TMO) Brings Biobased, Sustainable Films for BPCs
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...